Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1Completed 1Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Multiple Myeloma 21Precursor Cell Lymphoblastic Leukemia-Lymphoma 6Burkitt Lymphoma 6Leukemia, Biphenotypic, Acute 5Recurrence 3Smoldering Multiple Myeloma 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 2Lymphoma, T-Cell 2Lymphoma, Large B-Cell, Diffuse 2Immunoglobulin Light-chain Amyloidosis 2Hodgkin Disease 2Blastic Plasmacytoid Dendritic Cell Neoplasm 2Renal Insufficiency 1Proteostasis Deficiencies 1Neoplasms, Plasma Cell 1Neoplasms 1Meningioma 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma, B-Cell 1Lymphoma 1Lymphodepleting Chemotherapy 1Lung Neoplasms 1Leukemia, Myelomonocytic, Chronic 1Leukemia 1Hematologic Neoplasms 1Down Syndrome 1Cytokine Release Syndrome 1Carcinoma, Non-Small-Cell Lung 1Carcinoma 1

Interventions

Cytarabine 2pegaspargase 1merphos 1hydrocortisone hemisuccinate 1dexamethasone acetate 1dexamethasone 21-phosphate 1calaspargase pegol 1blinatumomab 1azathiopurine 1auricularum 1Vincristine 1Spinal Puncture 1Specimen Handling 1Radiotherapy, Conformal 1Nivolumab 1N,N-dicyclohexyl-isoborneol-10-sulfonamide 1Methotrexate 1Mercaptopurine 1Idarubicin 1Hydrocortisone 1Etoposide 1Dexamethasone 1Daunorubicin 1Calcium Dobesilate 1Biopsy 1Asparaginase 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Down Syndrome × Calcium Dobesilate × Clear all
NCT04546399 2025-09-10

A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)

National Cancer Institute (NCI)

Phase 2 Recruiting
461 enrolled
Lymphoid

Burkitt Lymphoma, Down Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡